Search results
Results from the WOW.Com Content Network
In 2001, Perlmutter left Merck and joined Amgen as the executive vice president and head of R&D from January 2001 to February 2012. In 2013, he replaced Peter S. Kim as the executive vice president and president of Merck Research Laboratories. [8] In 2020, he retired from Merck and was replaced by Dean Y. Li. [9]
mRNA-4157/V940 is an mRNA based cancer vaccine. When administered, it will produce one of several dozen possible abnormal proteins commonly found in cancerous tissues. The production of those proteins is intended to invoke an immune response. mRNA-4157/V940 is given to patients after their tumors have been sequenced and abnormal proteins ...
Merck has named a new head of research. Roger Perlmutter steps into the roles of executive vice president and president of Merck Research Laboratories. He replace of the retiring Peter Kim ...
Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, or variations of the bacteria, that the shot targeted in a variety of adult populations across studies.
Julie Gerberding, Merck Chief Patient Officer and Former CDC Director joins Yahoo Finance’s On The Move to break down the company’s search for a coronavirus vaccine.
Peter S. Kim (born April 27, 1958) is an American scientist. He was president of Merck Research Laboratories (MRL) 2003–2013 and is currently Virginia & D.K. Ludwig Professor of Biochemistry at Stanford University, Institute Scholar at Stanford ChEM-H, and Lead Investigator of the Infectious Disease Initiative at the Chan Zuckerberg Biohub.
This pharmacology -related article is a stub. You can help Wikipedia by expanding it.
Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a mid ...